AstraZeneca is discontinuing the CAPItello-280 Phase III trial evaluating the efficacy and safety of Truqap (capivasertib) in combination with docetaxel and androgen-deprivation therapy (ADT) compared ...

RxDx Device is an immunohistochemistry (IHC) assay combined with a digital pathology algorithm to determine patient treatment. The device uses artificial intelligence-based image analysis with a level ...

Positive recommendation based on clinical, real-world and bioequivalence data supporting feasibility and safety of Phesgo’s administration outside of clinical settings, for example at home1-4Phesgo ...

As we have highlighted in prior blog posts, the ability to augment design characteristics with custom R code is especially relevant to the ever-evolving therapeutic area of oncology. As regulatory ...

Novavax, Inc. (Nasdaq: NVAX) today announced the appointment of Charles Newton to its board as an independent director. Mr. Newton brings extensive experience in public markets and healthcare ...

Results from Operations for first quarter 2025 versus first quarter last year:Revenue: $3.35 billion versus $3.18 billionDiluted EPS: $2.52 versus $2.69Adjusted EPS: $3.84 versus $3.68Reaffirmed ...

Effective July 1, 2025, he will succeed Oliver Rittgen who has decided to pursue a career opportunity outside of Bayer after 25 years with the company / Guru Ramamurthy has extensive expertise in ...

On the last day of February every year is Rare Disease Day, a dedicated day to celebrate the rare disease community, including patients, families, caregivers, clinicians, researchers, regulators, and ...

AXON NAMES NEW PRESIDENT AND MANAGING PARTNER, TINA HAHN, AS RALPH SUTTON CHANGES LANEApril 30, 2025—Tina Hahn, who joined AXON in 2012 as Vice President, will now take on the role of AXON’s President ...

Total Q1 sales £7.5 billion +2% AER; +4% CERSpecialty Medicines sales £2.9 billion (+17%); Respiratory, Immunology and Inflammation £0.8 billion (+28%); Oncology £0.4 billion (+53%); HIV sales £1.7 ...

Dr. Marvin Hausman is joining Exousia Pro as a Consultant and will host a weekly series. ORLANDO, FL / ACCESS Newswire / April 30, 2025 / MARIJUANA INC. (OTCPINK:MAJI), dba Exousia Pro, Inc., a ...

New findings to be presented at the 2025 European Association for the Study of the Liver (EASL) Congress continue to demonstrate the effectiveness of Livdelzi (seladelpar) in reducing pruritus in ...